https://www.lavfund.com/ 2025-09-11T01:23:36-07:00 daily https://www.lavfund.com/portfolio 2025-09-11T01:23:36-07:00 daily https://www.lavfund.com/about-us 2025-09-11T01:23:36-07:00 daily https://www.lavfund.com/news 2025-09-11T01:23:36-07:00 daily https://www.lavfund.com/contact-us 2025-09-11T01:23:36-07:00 daily https://www.lavfund.com/blog/insilico-medicine-secures-37m-in-series-b-funding 2019-09-10T17:54:09-07:00 daily https://www.lavfund.com/blog/ionova-raises-us-17-million-series-a-funding-to-accelerate-oncology 2019-10-14T23:51:41-07:00 daily https://www.lavfund.com/blog/dmed-raises-nearly-us-50-million-in-series-b-financing-to-strengthen-and 2019-10-17T09:44:36-07:00 daily https://www.lavfund.com/blog/ansun-biopharma-secures-80-million-in-series-b-financing 2019-10-16T13:02:21-07:00 daily https://www.lavfund.com/blog/carsgen-therapeutics-officially-listed-on-hkex 2021-06-19T12:16:22-07:00 daily https://www.lavfund.com/blog/fountain-medical-development-limited-announces-62-mm-series-d-round 2019-10-25T08:30:56-07:00 daily https://www.lavfund.com/blog/terns-pharmaceuticals-receives-fast-track-designation-from-fda-for-tern-101 2019-10-30T09:55:15-07:00 daily https://www.lavfund.com/blog/gracell-announces-progressive-outcomes-from-multiple-human-clinical-trials-to 2019-12-19T16:16:00-08:00 daily https://www.lavfund.com/blog/tmunity-raises-75-million-in-series-b-financing-to-advance-next-generation 2019-10-31T13:25:02-07:00 daily https://www.lavfund.com/blog/harpoon-therapeutics-and-abbvie-announce-licensing-and-option-collaboration 2019-11-24T12:31:41-08:00 daily https://www.lavfund.com/blog/elpiscience-completes-series-b-financing-of-usd-100-million 2019-12-31T12:38:16-08:00 daily https://www.lavfund.com/blog/alebund-pharmaceuticals-closes-nearly-rmb-200-million-pre-c-round-financing 2023-04-12T10:59:40-07:00 daily https://www.lavfund.com/blog/remegen-debuts-on-hong-kong-stock-exchange 2020-11-16T10:34:39-08:00 daily https://www.lavfund.com/blog/transcenta-holding-secures-100-million-series-b-plus-financing 2020-01-10T08:35:20-08:00 daily https://www.lavfund.com/blog/abbisko-therapeutics-announces-70m-series-c-financing-led-by-temasek 2020-03-25T10:54:12-07:00 daily https://www.lavfund.com/blog/tempest-therapeutics-announces-fda-clearance-of-investigational-new-drug 2020-01-31T08:57:40-08:00 daily https://www.lavfund.com/blog/black-diamond-therapeutics-announces-closing-of-initial-public-offering-and 2020-02-04T18:31:18-08:00 daily https://www.lavfund.com/blog/insilico-medicine-raises-255-million-in-series-c-financing 2021-06-22T11:16:49-07:00 daily https://www.lavfund.com/blog/inventisbio-completes-147-million-series-d-financing 2020-09-28T10:48:25-07:00 daily https://www.lavfund.com/blog/passage-bio-announces-pricing-of-initial-public-offering 2020-02-28T18:28:30-08:00 daily https://www.lavfund.com/blog/ansun-biopharma-announces-positive-results-from-investigator-initiated-trial 2020-04-02T14:31:07-07:00 daily https://www.lavfund.com/blog/legend-biotech-announces-pricing-of-initial-public-offering 2020-06-06T22:55:10-07:00 daily https://www.lavfund.com/blog/remegen-completes-usd-100-million-plus-in-funding 2020-04-03T09:10:56-07:00 daily https://www.lavfund.com/blog/eluminex-biosciences-an-ophthalmology-focused-biotechnology 2020-11-20T00:32:08-08:00 daily https://www.lavfund.com/blog/biontech-and-dualitybio-form-global-strategic-partnership-to-accelerate 2023-04-03T18:31:46-07:00 daily https://www.lavfund.com/blog/burning-rock-announces-pricing-of-initial-public-offering 2020-06-13T11:44:41-07:00 daily https://www.lavfund.com/blog/arrivent-biopharma-launches-with-up-to-150m-in-series-a-financing-and 2021-06-30T10:00:41-07:00 daily https://www.lavfund.com/blog/gracell-reports-data-of-first-in-human-clinical-trial-for-universal-truucar 2020-04-29T22:20:48-07:00 daily https://www.lavfund.com/blog/scineuro-pharmaceuticals-launches-to-bring-innovative-treatments-for-cns 2020-12-09T10:42:21-08:00 daily https://www.lavfund.com/blog/peijia-medical-debuts-on-hong-kong-stock-exchange 2020-05-15T14:27:53-07:00 daily https://www.lavfund.com/blog/qihan-biotech-raises-additional-67-million-in-series-a-financing 2021-03-28T23:43:47-07:00 daily https://www.lavfund.com/blog/insilico-medicine-signs-strategic-research-collaboration-with-sanofi-worth-up 2022-11-08T10:51:42-08:00 daily https://www.lavfund.com/blog/jacobio-debuts-on-hong-kong-stock-exchange 2020-12-29T08:32:52-08:00 daily https://www.lavfund.com/blog/chugai-and-alebund-enter-into-option-and-license-agreement-for-eos789-under 2021-07-09T11:59:20-07:00 daily https://www.lavfund.com/blog/profoundbio-announces-completion-of-more-than-55-million-series-a-financing 2021-07-12T10:01:20-07:00 daily https://www.lavfund.com/blog/transcenta-closes-105-million-in-crossover-financing 2020-12-23T10:12:28-08:00 daily https://www.lavfund.com/blog/singleron-completes-30-million-series-a-financing 2020-09-08T23:59:01-07:00 daily https://www.lavfund.com/blog/abbisko-therapeutics-announces-the-completion-of-123-million-series-d 2021-01-12T22:15:41-08:00 daily https://www.lavfund.com/blog/dizal-pharmaceuticals-announced-the-closing-of-us-100-million-new-round-of 2020-08-18T23:22:08-07:00 daily https://www.lavfund.com/blog/edigene-announces-approval-of-its-ind-application-for-its-crispr-cas-9 2021-01-18T11:28:29-08:00 daily https://www.lavfund.com/blog/cansinobio-s-successful-listing-on-star-market-makes-it-the-initial-dual 2020-12-08T23:16:43-08:00 daily https://www.lavfund.com/blog/gracell-biotechnologies-announces-pricing-of-initial-public-offering 2021-01-09T13:08:07-08:00 daily https://www.lavfund.com/blog/abbvie-and-jacobio-announce-strategic-collaboration-to-advance-shp2-inhibitors 2020-06-01T12:22:09-07:00 daily https://www.lavfund.com/blog/eluminex-biosciences-exclusively-licenses-fibrogen-s-biosynthetic-cornea 2021-07-19T12:04:28-07:00 daily https://www.lavfund.com/blog/connect-biopharma-completes-115-million-series-c-financing 2020-08-24T11:30:40-07:00 daily https://www.lavfund.com/blog/sansure-biotech-debuts-on-star-market 2020-08-28T17:28:04-07:00 daily https://www.lavfund.com/blog/edigene-raises-approximately-usd-67-million-in-series-b-financing-to-advance 2020-10-13T12:43:47-07:00 daily https://www.lavfund.com/blog/lilly-and-kumquat-biosciences-announce-collaboration-to-discover-and-develop 2021-07-30T10:51:30-07:00 daily https://www.lavfund.com/blog/scivita-medical-completes-series-b-financing-of-nearly-rmb0-4-billion-to 2021-08-05T15:08:14-07:00 daily https://www.lavfund.com/blog/terns-pharmaceuticals-inc-announces-pricing-of-upsized-initial-public 2021-02-07T00:31:02-08:00 daily https://www.lavfund.com/blog/regor-therapeutics-announces-completion-of-90-million-series-b-financing 2021-02-19T10:38:37-08:00 daily https://www.lavfund.com/blog/pulnovo-medical-a-pioneer-medical-device-company-specializing-in-the 2021-08-04T11:57:47-07:00 daily https://www.lavfund.com/blog/insilico-medicine-achieves-industry-first-nominating-preclinical-candidate 2021-02-25T12:13:46-08:00 daily https://www.lavfund.com/blog/nmpa-approves-the-application-for-conditional-marketing-authorization-of 2021-02-25T13:11:18-08:00 daily https://www.lavfund.com/blog/allist-s-third-generation-egfr-tki-receives-marketing-approval-for-lung 2021-03-03T12:00:48-08:00 daily https://www.lavfund.com/blog/remegen-s-adc-cancer-drug-granted-conditional-marketing-approval-in-china 2021-06-10T09:41:16-07:00 daily https://www.lavfund.com/blog/seagen-and-remegen-announce-exclusive-worldwide-license-and-co-development 2021-08-09T12:21:07-07:00 daily https://www.lavfund.com/blog/gracell-biotechnologies-raises-100-million-in-series-c-funding-to-advance 2020-10-29T10:50:59-07:00 daily https://www.lavfund.com/blog/connect-biopharma-holdings-limited-announces-pricing-of-initial-public-offering 2021-03-20T12:15:48-07:00 daily https://www.lavfund.com/blog/meditrust-health-raises-over-2-billion-yuan-in-series-c-financing-esg-drives 2021-08-17T23:09:10-07:00 daily https://www.lavfund.com/blog/remegen-s-telitacicept-granted-conditional-marketing-approval-to-treat 2021-03-11T23:57:26-08:00 daily https://www.lavfund.com/blog/abbisko-therapeutics-announces-preliminary-phase-i-safety-and-efficacy 2022-12-16T00:11:13-08:00 daily https://www.lavfund.com/blog/merck-and-kelun-biotech-announce-exclusive-license-and-collaboration 2022-12-23T10:22:36-08:00 daily https://www.lavfund.com/blog/tempest-and-millendo-announce-proposed-merger-agreement 2021-03-30T09:56:59-07:00 daily https://www.lavfund.com/blog/edigene-raises-approximately-usd-62-million-in-series-b-plus-financing-and 2021-04-21T08:29:04-07:00 daily https://www.lavfund.com/blog/profoundbio-announces-completion-of-70-million-series-a-financing-to 2022-06-02T11:30:31-07:00 daily https://www.lavfund.com/blog/adarx-raises-75-million-to-advance-growing-pipeline 2021-09-08T16:46:35-07:00 daily https://www.lavfund.com/blog/nucleix-secures-55-million-funding-to-advance-lung-epicheck-for-early 2021-04-08T12:25:34-07:00 daily https://www.lavfund.com/blog/transcenta-debuts-on-hong-kong-stock-exchange 2021-09-29T17:42:43-07:00 daily https://www.lavfund.com/blog/alebund-pharmaceuticals-raises-60-million-in-series-b-financing-round-to 2021-07-09T12:00:47-07:00 daily https://www.lavfund.com/blog/building-diabetes-management-product-portfolio-microtech-medical-debuts-on 2021-10-19T18:00:57-07:00 daily https://www.lavfund.com/blog/ronovo-surgical-completes-series-a-financing-aims-to-transform-surgery-with 2021-04-24T09:05:23-07:00 daily https://www.lavfund.com/blog/shouti-secures-100-million-series-b-financing-to-accelerate-development-of 2021-10-20T11:18:59-07:00 daily https://www.lavfund.com/blog/scivita-medical-raises-nearly-rmb0-4-billion-in-series-a-funding-round-and 2021-04-26T12:09:01-07:00 daily https://www.lavfund.com/blog/glubio-completes-series-a-financing-of-22-million-to-advance-the 2022-08-01T09:22:39-07:00 daily https://www.lavfund.com/blog/rona-therapeutics-announces-exclusive-licensing-transaction-from-sanofi-for 2022-07-30T22:46:52-07:00 daily https://www.lavfund.com/blog/abbisko-cayman-limited-successfully-landed-on-the-hong-kong-stock-exchange 2021-10-15T23:34:32-07:00 daily https://www.lavfund.com/blog/alebund-pharmaceuticals-raises-54-5-million-in-series-b-financing-round-to 2021-09-14T14:27:39-07:00 daily https://www.lavfund.com/blog/elpiscience-announces-the-completion-of-105-million-series-c-financing 2021-05-13T09:09:28-07:00 daily https://www.lavfund.com/blog/singleron-completes-series-b-financing 2021-11-09T11:38:09-08:00 daily https://www.lavfund.com/blog/neukio-biotherapeutics-completed-series-a-1-financing-to-accelerate 2022-09-02T08:58:36-07:00 daily https://www.lavfund.com/blog/duality-biologics-completed-90-million-series-b-financing 2021-05-19T23:08:02-07:00 daily https://www.lavfund.com/blog/regor-and-lilly-enter-into-strategic-collaboration-to-discover-and-develop 2021-12-10T11:27:49-08:00 daily https://www.lavfund.com/blog/rgenta-therapeutics-announces-the-successful-completion-of-extension-of-seed 2021-05-25T16:36:45-07:00 daily https://www.lavfund.com/blog/nikang-therapeutics-announces-completion-of-200-million-series-c-financing 2021-05-26T15:51:20-07:00 daily https://www.lavfund.com/blog/synthekine-announces-107-5-million-oversubscribed-series-b-financing-to 2021-06-10T23:12:26-07:00 daily https://www.lavfund.com/blog/structure-therapeutics-announces-pricing-of-upsized-initial-public-offering 2023-02-04T22:46:52-08:00 daily https://www.lavfund.com/blog/biomarin-and-skyline-therapeutics-announce-strategic-collaboration-to-develop 2021-12-16T17:09:01-08:00 daily https://www.lavfund.com/blog/sperogenix-and-santhera-enters-into-exclusive-license-agreement-for 2024-02-13T12:01:18-08:00 daily https://www.lavfund.com/blog/eluminex-biosciences-closes-40-million-series-b-financing-to-continue-the 2023-02-27T16:55:18-08:00 daily https://www.lavfund.com/blog/china-s-nmpa-clears-phase-3-ind-application-for-alebund-pharmaceutical-s 2023-03-17T11:32:11-07:00 daily https://www.lavfund.com/blog/carvykti-ciltacabtagene-autoleucel-bcma-directed-car-t-therapy-receives 2022-02-28T22:47:33-08:00 daily https://www.lavfund.com/blog/impact-therapeutics-announces-phase-3-clinical-study-of-senaparib-for 2023-04-11T22:30:06-07:00 daily https://www.lavfund.com/blog/rona-therapeutics-announces-completion-of-33-million-series-a-financing-to 2022-04-07T11:19:25-07:00 daily https://www.lavfund.com/blog/nmpa-approves-the-nda-for-carsgen-s-bcma-car-t-therapy-zevorcabtagene 2024-03-01T11:52:36-08:00 daily https://www.lavfund.com/blog/abbisko-therapeutics-announces-worldwide-collaboration-with-lilly-to-discover 2024-02-13T12:01:18-08:00 daily https://www.lavfund.com/blog/gracell-biotechnologies-to-be-acquired-by-astrazeneca-furthering-cell 2023-12-26T19:43:50-08:00 daily https://www.lavfund.com/blog/profoundbio-raises-112-million-in-oversubscribed-series-b-equity-financing 2024-02-16T11:21:58-08:00 daily https://www.lavfund.com/blog/arrivent-announces-pricing-of-upsized-initial-public-offering 2024-01-27T13:24:01-08:00 daily https://www.lavfund.com/blog/rona-therapeutics-and-keymed-biosciences-announce-collaboration-to-discover 2023-05-16T10:19:20-07:00 daily https://www.lavfund.com/blog/scivita-medical-expands-collaboration-with-boston-scientific 2024-03-25T22:36:07-07:00 daily https://www.lavfund.com/blog/nda-of-agamree-was-accepted-and-granted-priority-review-by-china-s-cde 2024-03-27T10:47:18-07:00 daily https://www.lavfund.com/blog/impact-therapeutics-entered-into-global-partnership-with-eikon-therapeutics 2023-06-01T17:07:15-07:00 daily https://www.lavfund.com/blog/genmab-to-broaden-and-strengthen-oncology-portfolio-with-acquisition-of 2024-04-03T21:37:01-07:00 daily https://www.lavfund.com/blog/impact-therapeutics-presented-pivotal-phase-3-clinical-data-for-senaparib-as 2023-10-20T10:36:41-07:00 daily https://www.lavfund.com/blog/veritas-genetics-secures-30m-in-series-b-funding-expands-team-with-strategic 2019-01-16T09:47:18-08:00 daily https://www.lavfund.com/blog/hangzhou-just-biotherapeutics-ltd-secures-closing-of-series-b-financing 2019-01-16T09:44:22-08:00 daily https://www.lavfund.com/blog/lilly-and-nextcure-announce-collaboration-to-discover-and-develop-novel 2018-12-17T18:58:19-08:00 daily https://www.lavfund.com/blog/tp-therapeutics-completes-80-million-mezzanine-financing-co-led-by-foresite-9fa53766-ac21-48fa-9fe2-0d5c6cb0bc6e 2019-01-02T10:10:53-08:00 daily https://www.lavfund.com/blog/tempest-therapeutics-reports-proof-of-mechanism-data-for-first-in-class-ppar 2018-12-17T18:57:00-08:00 daily https://www.lavfund.com/blog/nextcure-raises-93-million-in-series-b-financing 2018-12-17T18:56:19-08:00 daily https://www.lavfund.com/blog/harpoon-therapeutics-announces-closing-of-70m-series-c-financing 2018-12-12T19:52:55-08:00 daily https://www.lavfund.com/blog/arrivent-biopharma-closes-155-million-oversubscribed-series-b-financing 2023-03-27T18:03:19-07:00 daily https://www.lavfund.com/blog/alector-initiates-phase-1-trial-of-al002-for-the-treatment-of-patients-with 2018-12-17T18:53:18-08:00 daily https://www.lavfund.com/blog/nextcure-initiates-clinical-development-for-nc318-a-siglec-15-targeting 2018-12-17T18:59:39-08:00 daily https://www.lavfund.com/blog/terns-pharmaceuticals-completes-80-million-series-b-financing-to-advance 2019-10-30T10:00:21-07:00 daily https://www.lavfund.com/blog/singlera-genomics-unveils-results-of-colones-study-demonstrating-detection-of 2019-01-09T17:40:22-08:00 daily https://www.lavfund.com/blog/tp-therapeutics-closes-45m-series-c-financing 2019-01-23T10:59:10-08:00 daily https://www.lavfund.com/blog/nextcure-inc-new-immuno-oncology-firm-announces-67-million-series-a 2019-01-23T11:07:02-08:00 daily https://www.lavfund.com/blog/acea-biosciences-announces-the-successful-completion-of-30-million-usd-in 2019-01-23T11:21:04-08:00 daily https://www.lavfund.com/blog/inventisbio-and-betta-pharma-to-co-develop-novel-drug-for-non-small-cell-lung 2018-12-30T22:42:31-08:00 daily https://www.lavfund.com/blog/mabspace-biosciences-merged-with-hangzhou-just-biotherapeutics-to-form 2019-01-01T18:35:08-08:00 daily https://www.lavfund.com/blog/ansun-and-tmunity-among-winners-of-2018-fierce-15 2019-01-01T15:33:57-08:00 daily https://www.lavfund.com/blog/harpoon-therapeutics-announces-filing-of-registration-statement-for-proposed 2018-12-30T15:55:03-08:00 daily https://www.lavfund.com/blog/agilent-to-expand-portfolio-and-capabilities-in-cell-analysis-with 2019-01-01T15:42:21-08:00 daily https://www.lavfund.com/blog/lilly-announces-agreement-to-acquire-armo-biosciences 2019-01-01T15:46:21-08:00 daily https://www.lavfund.com/blog/bluebird-bio-and-gritstone-oncology-announce-strategic-collaboration-to 2019-01-06T16:15:53-08:00 daily https://www.lavfund.com/blog/alector-initiates-phase-1-trial-of-al001-for-the-treatment-of-frontotemporal 2019-01-03T22:52:42-08:00 daily https://www.lavfund.com/blog/genome-editing-biotech-company-edigene-raises-15-million-in-series-pre-b 2019-01-06T16:09:07-08:00 daily https://www.lavfund.com/blog/singlera-genomics-and-fudan-university-unveil-results-showing-pan-cancer 2019-01-09T17:37:56-08:00 daily https://www.lavfund.com/blog/ksq-therapeutics-secures-80-million-financing-and-advances-broad-pipeline-of 2019-01-09T17:49:52-08:00 daily https://www.lavfund.com/blog/gritstone-oncology-announces-pricing-of-initial-public-offering 2019-01-09T17:53:03-08:00 daily https://www.lavfund.com/blog/veritas-genetics-breaks-1-000-whole-genome-barrier 2019-01-30T10:00:35-08:00 daily https://www.lavfund.com/blog/e-scape-bio-series-a-extension-brings-total-round-to-63-million-to-fund 2019-01-30T09:38:03-08:00 daily https://www.lavfund.com/blog/tmunity-therapeutics-inc-to-advance-ind-enabling-activities-for 2019-01-30T09:52:15-08:00 daily https://www.lavfund.com/blog/hangzhou-just-biotherapeutics-secures-35-million-series-b-financing 2019-01-14T10:54:10-08:00 daily https://www.lavfund.com/blog/impact-therapeutics-raises-30-million-in-series-c-financing 2019-01-14T10:36:10-08:00 daily https://www.lavfund.com/blog/alector-announces-133-million-in-series-e-financing-to-advance-broad 2019-01-14T10:40:28-08:00 daily https://www.lavfund.com/blog/avedro-announces-25-million-in-funding-to-fuel-innovation-and-commercial-growth 2019-01-14T11:15:45-08:00 daily https://www.lavfund.com/blog/ansun-biopharma-secures-85-million-in-series-a-financing 2019-01-14T11:09:45-08:00 daily https://www.lavfund.com/blog/tmunity-raises-additional-35-million-in-series-a-financing-bringing-series 2019-01-14T11:31:00-08:00 daily https://www.lavfund.com/blog/mabspace-initiated-global-phase-1-trial-of-msb2311-its-2nd-generation-pd-l1 2019-01-14T10:46:22-08:00 daily https://www.lavfund.com/blog/terns-pharmaceuticals-acquires-global-exclusive-rights-to-develop-and 2019-01-14T11:49:02-08:00 daily https://www.lavfund.com/blog/tempest-therapeutics-closes-70-million-series-b-financing 2019-01-14T11:55:48-08:00 daily https://www.lavfund.com/blog/singlera-genomics-raises-60-million-in-series-a-financing 2019-01-14T12:01:24-08:00 daily https://www.lavfund.com/blog/veritas-genetics-launches-collaboration-with-mayo-clinic-to-integrate-whole 2019-01-14T17:41:34-08:00 daily https://www.lavfund.com/blog/gritstone-oncology-secures-92-7-million-in-series-b-financing 2019-01-14T17:49:03-08:00 daily https://www.lavfund.com/blog/transcenta-holding-announces-licensing-agreement-with-lilly 2019-04-01T22:29:21-07:00 daily https://www.lavfund.com/blog/genome-editing-biotech-edigene-raises-10-million-in-series-pre-b-plus 2019-02-04T23:03:42-08:00 daily https://www.lavfund.com/blog/nuvera-medical-raises-15-million-in-new-financing 2019-02-07T10:14:23-08:00 daily https://www.lavfund.com/blog/alector-announces-pricing-of-initial-public-offering 2019-02-07T22:50:59-08:00 daily https://www.lavfund.com/blog/harpoon-therapeutics-announces-pricing-of-initial-public-offering 2019-02-09T21:39:26-08:00 daily https://www.lavfund.com/blog/passage-bio-launches-with-115-5-million-series-a-to-develop-aav-delivered 2019-02-15T08:04:50-08:00 daily https://www.lavfund.com/blog/burning-rock-announces-the-completion-of-the-series-c-financing-of-rmb-850 2019-02-15T08:18:45-08:00 daily https://www.lavfund.com/blog/avedro-announces-pricing-of-initial-public-offering 2019-02-15T07:55:41-08:00 daily https://www.lavfund.com/blog/cansino-manufacturing-facility-ground-breaking-and-contract-signing-ceremony 2019-02-20T10:07:05-08:00 daily https://www.lavfund.com/blog/mabspace-biosciences-secures-15-million-in-series-a-financing-from-lilly 2019-02-20T10:10:52-08:00 daily https://www.lavfund.com/blog/gracell-biotechnologies-completes-85-million-series-b-for-immune-cell-gene 2019-02-27T21:10:10-08:00 daily https://www.lavfund.com/blog/gracell-bio-announces-fast-car-t-a-breakthrough-technology-for-hematological 2019-04-24T09:53:05-07:00 daily https://www.lavfund.com/blog/nextcure-and-yale-publish-nature-medicine-paper-detailing-novel 2019-03-06T09:10:21-08:00 daily https://www.lavfund.com/blog/elpiscience-and-bio-techne-announce-strategic-collaboration 2019-04-24T10:06:34-07:00 daily https://www.lavfund.com/blog/clinical-stage-biotech-company-inventisbio-inc-closes-70-million-usd-series 2019-03-11T19:58:07-07:00 daily https://www.lavfund.com/blog/turning-point-therapeutics-announces-pricing-of-initial-public-offering 2019-04-17T21:41:08-07:00 daily https://www.lavfund.com/blog/first-vaccine-share-in-hong-kong-stock-cansinobio-announces-proposed-listing 2019-03-19T14:14:53-07:00 daily https://www.lavfund.com/blog/turning-point-therapeutics-files-registration-statement-for-proposed-initial 2019-03-23T11:36:32-07:00 daily https://www.lavfund.com/blog/jacobio-s-jab-3068-received-orphan-drug-designation-and-clearance-to-proceed 2019-06-18T00:11:00-07:00 daily https://www.lavfund.com/blog/gritstone-oncology-announces-clinical-acceleration-of-off-the-shelf 2019-04-24T10:28:17-07:00 daily https://www.lavfund.com/blog/x4-pharmaceuticals-and-abbisko-therapeutics-enter-into-oncology-development 2019-07-17T21:46:47-07:00 daily https://www.lavfund.com/blog/evotec-jump-starts-biologics-with-acquisition-of-just-biotherapeutics 2019-05-23T09:04:22-07:00 daily https://www.lavfund.com/blog/nextcure-announces-pricing-of-initial-public-offering-of-common-stock 2019-05-10T09:03:56-07:00 daily https://www.lavfund.com/blog/tempest-therapeutics-starts-phase-i-ib-clinical-trial-with-first-in-class 2019-05-17T10:05:19-07:00 daily https://www.lavfund.com/blog/lilly-announces-licensing-agreement-for-non-opioid-pain-asset-from-centrexion 2019-05-29T18:05:51-07:00 daily https://www.lavfund.com/blog/terns-pharmaceuticals-announces-exclusive-licensing-and-collaboration 2019-07-04T12:57:48-07:00 daily https://www.lavfund.com/blog/glaukos-and-avedro-announce-definitive-acquisition-agreement 2019-08-08T13:58:41-07:00 daily https://www.lavfund.com/blog/inhibrx-reports-phase-1-dose-escalation-results-of-inbrx-109-a-multivalent 2019-09-03T10:06:45-07:00 daily https://www.lavfund.com/blog/passage-bio-closes-110-million-series-b-financing 2019-09-05T10:39:54-07:00 daily https://www.lavfund.com/blog/impact-raises-rmb-400-million-in-series-d-funding 2024-04-19T13:21:49-07:00 daily https://www.lavfund.com/blog/ronovo-surgical-advances-commercialization-in-china-through-targeted 2025-09-06T21:42:56-07:00 daily https://www.lavfund.com/blog/johnson-johnson-to-acquire-proteologix-inc-to-lead-in-atopic-dermatitis 2024-05-16T12:17:27-07:00 daily https://www.lavfund.com/blog/the-phase-3-clinical-trial-data-of-senaparib-published-in-nature-medicine 2024-05-16T12:33:42-07:00 daily https://www.lavfund.com/blog/belief-biomed-and-takeda-china-jointly-announced-bbm-h901-dalnacogene 2025-04-10T20:45:10-07:00 daily https://www.lavfund.com/blog/abbvie-and-futuregen-announce-license-agreement-to-develop-next-generation 2024-06-13T11:20:08-07:00 daily https://www.lavfund.com/blog/syneron-bio-announces-strategic-collaboration-with-astrazeneca 2025-03-21T15:43:48-07:00 daily https://www.lavfund.com/blog/rona-therapeutics-raises-35-million-series-a-financing-to-advance 2024-07-20T13:01:20-07:00 daily https://www.lavfund.com/blog/alebund-pharmaceuticals-announces-collaboration-and-license-agreement-with-r1 2026-03-17T10:08:32-07:00 daily https://www.lavfund.com/blog/immuneonco-and-instil-bio-announce-license-and-collaboration-agreement-for 2024-08-01T18:22:06-07:00 daily https://www.lavfund.com/blog/syneron-bio-announces-completion-of-150-million-series-b-financing 2026-03-30T18:36:25-07:00 daily https://www.lavfund.com/blog/regor-enters-into-a-definitive-purchase-agreement-for-genentech-to-acquire 2024-09-30T13:08:12-07:00 daily https://www.lavfund.com/blog/gsk-enters-agreement-to-acquire-cmg1a46-from-chimagen-biosciences-to-expand 2024-10-30T10:58:40-07:00 daily https://www.lavfund.com/blog/impact-announces-completion-of-rmb-250-million-sr-d-financing 2024-11-18T11:36:27-08:00 daily https://www.lavfund.com/blog/duality-biologics-and-gsk-enter-into-exclusive-option-agreement-for-a-novel 2024-12-04T14:15:42-08:00 daily https://www.lavfund.com/blog/fda-approval-of-ensartinib-for-alk-positive-locally-advanced-or-metastatic 2024-12-19T15:37:41-08:00 daily https://www.lavfund.com/blog/agamree-for-dmd-treatment-was-approved-by-china-s-nmpa 2024-12-19T14:00:01-08:00 daily https://www.lavfund.com/blog/cornerstone-robotics-raises-over-us-70-million-funding-to-forge-accessibility 2025-01-13T11:49:20-08:00 daily https://www.lavfund.com/blog/alebund-pharmaceutical-announced-the-first-closing-of-rmb-550-million-in 2025-01-07T14:24:00-08:00 daily https://www.lavfund.com/blog/senaparib-approved-by-nmpa-for-1l-maintenance-therapy-in-ovarian-cancer 2025-01-17T20:02:09-08:00 daily https://www.lavfund.com/blog/categories 2026-03-31T01:36:25Z daily